Source study found

Story checked

Experimental Heart Drug Helps Patients Exercise More and Feel Better (opens in a new tab)

scitechdaily.com · 2026-10-12

Short answerEvidenceSource

Short answer

Mixed

Mixed.

2 key claims are not backed by the study. One other point was not covered by the paper.

3 supported
1 overstated
2 not supported
1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Experimental Heart Drug Helps Patients Exercise More and Feel Better

scitechdaily.com · 2026-10-12

The story’s checkable claims.

Read the original story

NewsLink checks it

Mixed

Three claims go beyond the study. One overstates it and two aren't supported at all. One claim the study doesn't address.

3 supported
1 overstated
2 not supported
1 not covered

Open claim evidence

The source study

Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy

The New England Journal of Medicine · 2026

Open source record Open in Tessa

Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

The study this story reportspresented as the new finding
Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
The New England Journal of Medicine · 2026
PubMed (opens in a new tab)Full Tessa analysis (opens in a new tab)
The study this story reportspresented as the new finding
Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
Circulation · 2026
PubMed (opens in a new tab)Full Tessa analysis (opens in a new tab)

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7Not supportedThe companion Circulation study found that compared with placebo, aficamten reduced signs of excessive contraction and improved several measures of diastolic function, including tissue Doppler measurements, left-ventricular blood-volume measures, and cardiac stress markers.View evidenceHide evidence

Why this verdict

The supplied paper profile does not include the companion Circulation imaging study or any reported outcomes on excessive contraction, tissue Doppler measures, left-ventricular blood-volume measures, diastolic function, or cardiac stress markers. These claims cannot be supported from the supplied profile.

Claim 2 of 7Not supportedAn ongoing extension study is following people with both forms of hypertrophic cardiomyopathy to assess aficamten’s effects over a longer period.View evidenceHide evidence

Why this verdict

The supplied profile reports treatment and safety monitoring in the trial for up to 72 weeks, but it does not mention an ongoing extension study or that it follows patients with both obstructive and nonobstructive HCM. This assertion is not supported by the supplied paper profile.

Study evidence

Reversible reductions in left ventricular ejection fraction to less than 50% occurred in 27 patients (10.5%) receiving aficamten and in 2 patients (0.8%) receiving placebo.Absolute difference 9.7 percentage points (10.5% vs 0.8%)

“...receive aficamten ... or placebo for up to 72 weeks.”

Claim 3 of 7OverstatedTwo new studies found that aficamten improved exercise capacity and reported health in people with nonobstructive hypertrophic cardiomyopathy (nHCM).View evidenceHide evidence

Why this verdict

The supplied paper profile supports one phase 3 randomized trial showing improvements in peak VO2 and KCCQ-CSS versus placebo. The claim is overstated because it frames the evidence as coming from “two new studies,” while the supplied profile contains only the ACACIA-HCM trial and does not substantiate a second study making the same exercise-capacity and reported-health finding.

Study evidence

Change in peak oxygen uptake (peak VO2) from baseline to week 36 favored aficamten vs placebo.Least-squares mean difference 0.67 ml·kg⁻¹·min⁻¹ (95% CI 0.22 to 1.11); P = 0.003.

“In this phase 3, multinational, double-blind trial, we randomly assigned adults with symptomatic nonobstructive HCM in a 1:1 ratio to receive aficamten ... or placebo for up to 72 weeks.”

Study evidence

At 36 weeks, aficamten produced a greater improvement in KCCQ clinical summary score than placebo.Least-squares mean difference 3.0 points (95% CI, 0.5 to 5.5); P = 0.02. Mean within-group changes: aficamten +11.4 points (95% CI, 9.6 to 13.2); placebo +8.4 points (95% CI, 6.6 to 10.2).

“The dual primary end points were the change from baseline to week 36 in peak oxygen uptake and in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS).”

Claim 4 of 7Not coveredThe article says these findings raise the possibility that aficamten affects the underlying disease process as well as relieves symptoms, though longer follow-up is needed to determine whether the changes last.View evidenceHide evidence

Why this verdict

The abstract-level profile supports symptomatic and functional improvements at 36 weeks, but it does not provide evidence that aficamten may affect the underlying disease process, nor does it report durability of such changes. The hedged statement may come from full-text discussion or external imaging data, but it is not verifiable from the supplied abstract-depth profile.

Study evidence

Change in peak oxygen uptake (peak VO2) from baseline to week 36 favored aficamten vs placebo.Least-squares mean difference 0.67 ml·kg⁻¹·min⁻¹ (95% CI 0.22 to 1.11); P = 0.003.

“In this phase 3, multinational, double-blind trial, we randomly assigned adults with symptomatic nonobstructive HCM in a 1:1 ratio to receive aficamten ... or placebo for up to 72 weeks.”

Study evidence

“The dual primary end points were the change from baseline to week 36 in peak oxygen uptake and in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS).”

Claim 5 of 7SupportedIn a new trial, an experimental drug helped patients with an inherited heart muscle condition feel better and exercise more.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that aficamten, in a randomized double-blind placebo-controlled phase 3 trial in symptomatic nonobstructive HCM, produced greater improvements than placebo in exercise capacity measured by peak VO2 and patient-reported health status measured by KCCQ-CSS at 36 weeks. The headline is broad but does not materially outrun the body as presented.

Study evidence

Change in peak oxygen uptake (peak VO2) from baseline to week 36 favored aficamten vs placebo.Least-squares mean difference 0.67 ml·kg⁻¹·min⁻¹ (95% CI 0.22 to 1.11); P = 0.003.

“In this phase 3, multinational, double-blind trial, we randomly assigned adults with symptomatic nonobstructive HCM in a 1:1 ratio to receive aficamten ... or placebo for up to 72 weeks.”

Study evidence

“The dual primary end points were the change from baseline to week 36 in peak oxygen uptake and in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS).”

Claim 6 of 7SupportedIn the trial reported in The New England Journal of Medicine, 517 participants received aficamten or a placebo, and after 36 weeks the aficamten group showed greater improvements in reported health status and peak oxygen consumption.View evidenceHide evidence

As stated517 participants; 36 weeks

Why this verdict

Supported by the abstract profile: 517 participants were randomized, the co-primary efficacy endpoints were assessed at week 36, and aficamten showed greater improvement than placebo in peak VO2 and KCCQ-CSS. The stated sample size and timepoint match the profile.

Study evidence

Change in peak oxygen uptake (peak VO2) from baseline to week 36 favored aficamten vs placebo.Least-squares mean difference 0.67 ml·kg⁻¹·min⁻¹ (95% CI 0.22 to 1.11); P = 0.003.

“In this phase 3, multinational, double-blind trial, we randomly assigned adults with symptomatic nonobstructive HCM in a 1:1 ratio to receive aficamten ... or placebo for up to 72 weeks.”

Study evidence

“The dual primary end points were the change from baseline to week 36 in peak oxygen uptake and in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS).”

Claim 7 of 7SupportedThe benefits came with a need for careful monitoring because a reversible decline in a measure of the heart’s pumping ability occurred more often with aficamten than with placebo.View evidenceHide evidence

Why this verdict

Supported. The abstract reports reversible reductions in LVEF to less than 50% in 27 patients receiving aficamten versus 2 receiving placebo, a substantially higher frequency with aficamten. Framing this as requiring careful monitoring is consistent with the reported safety signal, although the abstract does not provide detailed monitoring protocols.

Study evidence

“...receive aficamten ... or placebo for up to 72 weeks.”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

The reported between-group effect sizes were modest in absolute terms: peak VO2 least-squares mean difference 0.67 ml·kg⁻¹·min⁻¹ and KCCQ-CSS least-squares mean difference 3.0 points.
The story says outcomes improved but, as presented, does not include the numerical effect sizes. Omitting magnitude can affect interpretation of how large the benefit was.
From Phase 3 randomized double-blind placebo-controlled trial (ACACIA-HCM); Phase 3 randomized, double-blind, placebo-control
Both aficamten and placebo groups improved from baseline in KCCQ-CSS, with the paper’s key health-status result being the between-group difference; the abstract profile does not provide a minimal clinically important difference threshold.
The story presents patient-reported health status as improved with aficamten but does not mention that the placebo group also improved or that clinical-significance thresholds are not available in the abstract.
From Phase 3 randomized, double-blind, placebo-controlled trial
Detailed safety information—event types, relatedness, timing, severity, adjudication, and management—is not available at abstract depth.
The story notes monitoring concerns but does not reflect the abstract-level limitation that detailed safety characterization is not available in the supplied evidence.
From Phase 3 randomized, double-blind, placebo-controlled trial (ACACIA-HCM)
The supplied paper profile does not report companion imaging outcomes, diastolic-function measures, cardiac stress-marker changes, or disease-process modification claims.
The story includes companion-study imaging and disease-process language, but those elements are outside the supplied abstract-level profile and are not reflected in the paper evidence provided here.
From Phase 3 randomized double-blind placebo-controlled trial (ACACIA-HCM); Phase 3 randomized, double-blind, placebo-control

4 things the story did carry across

The paper profile’s central evidence is a phase 3 multinational, randomized, double-blind, placebo-controlled trial of aficamten versus placebo in adults with symptomatic nonobstructive HCM.
The co-primary efficacy endpoints were change from baseline to week 36 in peak oxygen uptake and KCCQ clinical summary score.
Reversible reductions in LVEF to less than 50% were more frequent with aficamten than placebo.
Longer-term efficacy durability beyond the 36-week co-primary endpoint is not detailed in the abstract-level profile.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate whether aficamten improves exercise capacity in adults with symptomatic nonobstructive hypertrophic cardiomyopathy versus placebo (change in peak oxygen uptake at 36 weeks).Phase 3 randomized double-blind placebo-controlled trial (ACACIA-HCM)Expand

In plain English

Phase 3, randomized, double-blind, placebo-controlled trial (ACACIA-HCM) evaluated aficamten versus placebo in adults with symptomatic nonobstructive hypertrophic cardiomyopathy. Co-primary endpoints were change from baseline to week 36 in peak oxygen uptake (peak VO2) and KCCQ-CSS. At 36 weeks, aficamten produced a statistically significant greater increase in peak VO2 (LS mean difference 0.67 ml·kg⁻¹·min⁻¹) versus placebo. Aficamten also produced a statistically significant greater improvement in KCCQ-CSS (LS mean difference 3.0 points). Reversible reductions in LVEF to <50% and higher rates of serious adverse events were more frequent with aficamten.

Key findings

Change in peak oxygen uptake (peak VO2) from baseline to week 36 favored aficamten vs placebo.Least-squares mean difference 0.67 ml·kg⁻¹·min⁻¹ (95% CI 0.22 to 1.11); P = 0.003.
Change in Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) from baseline to week 36 favored aficamten vs placebo.Least-squares mean difference 3.0 points (95% CI 0.5 to 5.5); P = 0.02.

“In this phase 3, multinational, double-blind trial, we randomly assigned adults with symptomatic nonobstructive HCM in a 1:1 ratio to receive aficamten ... or placebo for up to 72 weeks.”

What this piece can’t prove

1 further detail could not be confirmed from the summary.

2human in vivoEvaluate whether aficamten improves patient-reported health status versus placebo (change in KCCQ clinical summary score at 36 weeks).Phase 3 randomized, double-blind, placebo-controlled trialExpand

In plain English

In the phase 3 ACACIA-HCM randomized, double-blind trial, aficamten produced a statistically greater improvement than placebo in patient-reported health status (KCCQ-CSS) at 36 weeks (least-squares mean difference 3.0 points, 95% CI 0.5 to 5.5; P = 0.02). Both groups showed within-group improvement from baseline.

Key findings

At 36 weeks, aficamten produced a greater improvement in KCCQ clinical summary score than placebo.Least-squares mean difference 3.0 points (95% CI, 0.5 to 5.5); P = 0.02. Mean within-group changes: aficamten +11.4 points (95% CI, 9.6 to 13.2); placebo +8.4 points (95% CI, 6.6 to 10.2).

“The dual primary end points were the change from baseline to week 36 in peak oxygen uptake and in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS).”

What this piece can’t prove

The abstract reports the co-primary endpoints together; secondary and longer-term outcomes (beyond week 36) are not detailed here.

1 further detail could not be confirmed from the summary.

3human in vivoCharacterize safety and tolerability of aficamten versus placebo over up to 72 weeks, including reversible reductions in left ventricular ejection fraction and serious adverse events.Phase 3 randomized, double-blind, placebo-controlled trial (ACACIA-HCM)Expand

In plain English

In the ACACIA-HCM phase 3 randomized, double-blind trial of symptomatic nonobstructive HCM, aficamten (starting 5 mg, up to 20 mg) was associated with higher rates of reversible reductions in left ventricular ejection fraction (LVEF <50%) and a higher proportion of serious adverse events during treatment exposure of up to 72 weeks compared with placebo, as reported in the trial abstract.

Key findings

Reversible reductions in left ventricular ejection fraction to less than 50% occurred in 27 patients (10.5%) receiving aficamten and in 2 patients (0.8%) receiving placebo.Absolute difference 9.7 percentage points (10.5% vs 0.8%)
Serious adverse events occurred in 52 patients (20.2%) receiving aficamten and in 38 patients (14.7%) receiving placebo.Absolute difference 5.5 percentage points (20.2% vs 14.7%)